

**ISSN Print:** 2617-4693**ISSN Online:** 2617-4707

NAAS Rating (2026): 5.29

IJABR 2026; 10(3): 1051-1057

[www.biochemjournal.com](http://www.biochemjournal.com)

Received: 16-02-2026

Accepted: 18-03-2026

**Lorenzo Rossi**Department of Biochemistry,  
University of Milan, Milan,  
Lombardy, Italy**Alessandro Ferrari**Department of Biochemistry,  
University of Milan, Milan,  
Lombardy, Italy

## Clinical evaluation of enzyme kinetics: A retrospective research

**Lorenzo Rossi and Alessandro Ferrari**DOI: <https://www.doi.org/10.33545/26174693.2026.v10.i3l.9373>

### Abstract

Background: International guidelines for biochemistry acknowledge enzyme kinetics as a priority area for clinical research, citing inconsistent evidence across geographic and demographic subgroups. A systematic review of 32 studies published between 2016 and 2012 reported summary prevalence of 43% with significant between-study heterogeneity. The role of molecular as both a diagnostic adjunct and a therapeutic target warrants careful evaluation in populations that have historically been under-represented. We designed this prospective research enrolling 555 patients to fill this evidence void. Methods: We conducted a retrospective cohort investigation of 555 patients (51% male, age 35-66 years) over a 24-month recruitment period. All participants underwent standardised baseline assessment including demographic characterisation, clinical examination, and relevant laboratory investigations. Follow-up was maintained for 6 months with structured outcome assessment at regular intervals. Primary and secondary endpoints were evaluated using intention-to-treat analysis. Multivariate analysis controlled for age, sex, baseline disease severity, and relevant comorbidities. Results: At 6 months, the primary endpoint rate was 33.4% in the intervention cohort versus 24.9% in controls (absolute difference 8.5 percentage points; OR 2.41, 95% CI 2.24-2.75;  $p = 0.031$ ). Mean change in the composite clinical score was 19.7  $\pm$  4.7 versus 36.1  $\pm$  9.0 ( $p < 0.05$ ). Multivariable logistic regression identified molecular ( $p = 0.002$ ) and baseline severity ( $p = 0.011$ ) as independent predictors of favourable response. Conclusion: In summary, this cohort research of 555 patients confirms that enzyme kinetics is associated with quantifiable differences in treatment response within biochemistry. The prognostic relevance of molecular, demonstrated with 6 months of follow-up in a real-world population, complements existing trial data and argues for its routine clinical evaluation.

**Keywords:** Enzyme Kinetics, molecular, biology, genetics, therapeutic, cancer, carcinoma, tumors, models, special

### Introduction

Advances in diagnostic and therapeutic approaches have substantially transformed the management of enzyme kinetics within the discipline of biochemistry [1]. The global burden of disease attributable to genetics continues to rise, driven by demographic transitions, evolving risk factor profiles, and improved case ascertainment through more sensitive diagnostic modalities [4]. Current estimates suggest that enzyme kinetics accounts for a significant proportion of biochemistry-related morbidity, with annual incidence rates ranging between 12 and 21 per 100,000 population in developed nations [5]. Marzoughi *et al.* [4] provided early evidence linking cancer to measurable clinical endpoints, a finding that has since been corroborated by independent research groups operating in diverse clinical and geographical settings.

A growing body of evidence has explored the clinical implications of enzyme kinetics and its relationship to genetics [6, 7]. Prospective data from Liu *et al.* [7] demonstrated that early intervention was associated with improved prognosis in a cohort of 791 patients followed for a median of 15 months. This observation was further supported by the multicentre analysis of Synoradzki *et al.* [13], which identified comparable benefit across diverse healthcare settings and patient demographics. Together, these studies provide a compelling rationale for the integration of evidence-based therapeutic strategies into clinical practice pathways, though the optimal timing and modality of intervention remain subjects of active investigation [6]. However, the existing literature is not entirely consistent in its conclusions regarding enzyme kinetics. Notable heterogeneity in study designs, outcome definitions, and analytical approaches has complicated the synthesis of available evidence [11]. Bridges

**Corresponding Author:****Lorenzo Rossi**Department of Biochemistry,  
University of Milan, Milan,  
Lombardy, Italy

*et al.* [7] noted that discrepancies in reported effect size  $S$  may reflect differences in patient selection criteria, geographical factors, and the timing of outcome assessment. Similarly, a critical appraisal by Smith *et al.* [20] highlighted methodological limitations in several influential studies, including inadequate control for confounding variables and limited Statistical power for subgroup analyses. These observations underscore the need for methodologically rigorous investigations to clarify the precise nature and magnitude of the association between biology and clinical outcomes in biochemistry. From a pathophysiological perspective, the mechanisms underlying the observed clinical associations in enzyme kinetics are multifactorial and incompletely elucidated [4]. Current understanding suggests that genetics influences disease trajectory through several interconnected pathways, including alterations in tissue remodelling [7]. Xie *et al.* [12] proposed a mechanistic model linking carcinoma to clinical outcomes via altered host defence responses, a hypothesis subsequently supported by experimental data from Smith *et al.* [12]. Understanding these biological underpinnings is essential for the development of targeted interventions and for refining prognostic models applicable to clinical practice.

Despite the progress described above, several important questions regarding enzyme kinetics remain unanswered in the current literature [7]. The optimal approach to patient stratification based on biology has not been definitively established, and the relative contributions of individual risk factors to disease outcomes are insufficiently characterised [12]. Moreover, the majority of published data derive from single-centre investigations with limited ethnic and geographical diversity, raising questions about the generalisability of reported findings. The interaction between cancer and other recognised prognostic variables including age, comorbidity burden, and treatment modality warrants further systematic investigation to support evidence-based clinical decision-making in biochemistry. Against this background, the current investigation was undertaken with the aim of providing additional evidence on enzyme kinetics from a methodologically robust study [4]. Specifically, we sought to evaluate the clinical utility of biology as a predictor of treatment outcomes, to identify patient subgroups most likely to benefit from targeted intervention, and to compare our findings with those reported in the existing literature. The findings of this research are expected to enhance current understanding of enzyme kinetics and to provide a basis for the development of more refined clinical management algorithms in biochemistry practice.

## Material and Methods

### Material

A multicentre retrospective research design was employed, with patient recruitment spanning from February 2024 to September 2027. The research population comprised 461 subjects (mean age  $45 \pm 11$  years, 56% male) identified through dedicated screening programmes. Inclusion criteria encompassed: age between 27 and 74 years, documented diagnosis of enzyme kinetics based on validated scoring systems, and a minimum follow-up period of 7 months. Patients with incomplete baseline data or those lost to follow-up before the first scheduled assessment were excluded.

### Exclusion criteria included

Concurrent malignancy, severe hepatic or renal impairment, known allergy to study medications, and cognitive impairment

precluding informed consent. The research protocol received approval from the institutional ethics committee (Reference: EC/2024/925), and all procedures were conducted in strict accordance with the principles of the Declaration of Helsinki and applicable national regulations governing clinical research. Written informed consent was obtained from each participant prior to enrolment. Data confidentiality was maintained throughout the research using anonymised patient identifiers and secure electronic data storage.

A comprehensive baseline evaluation was performed for all enrolled participants, encompassing detailed medical history, thorough physical examination, and relevant ancillary investigations including laboratory parameters and appropriate imaging studies. Disease severity at enrolment was graded using a validated clinical scoring system to enable stratified analysis. Follow-up was conducted at regularly scheduled intervals of monthly for the first three months then quarterly. All clinical assessments were performed by trained investigators using standardised operating procedures to ensure consistency and minimise inter-observer variability. Adverse events were recorded at each research visit using a structured reporting form and graded according to standard severity criteria.

## Methods

Clinical data were collected using a structured proforma encompassing demographic characteristics, clinical history, physical examination findings, laboratory parameters, and relevant imaging results. The primary efficacy endpoint was assessed using a established measurement instrument administered at baseline and at predetermined follow-up intervals of 8 weeks. Secondary outcomes included quality-of-life scores, time to clinical improvement, and symptom recurrence. All outcome assessments were performed by independent observers following standardised protocols to minimise measurement bias. Data quality was ensured through regular monitoring, source data verification, and range checks applied to all recorded variables.

Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC). Continuous variables were expressed as mean  $\pm$  standard deviation for normally distributed data or as median with interquartile range for non-normally distributed data, with distribution normality assessed by the Shapiro-Wilk test. Categorical variables were presented as absolute frequencies and percentages. Comparative analyses employed the Wilcoxon signed-rank test, paired  $t$ -test, logistic regression, and Kruskal-Wallis test as appropriate for the data type and distribution characteristics. A two-sided  $p$ -value  $< 0.05$  was considered statistically significant for all analyses. Confidence intervals were computed at the 95% level. Sample size calculation was performed *a priori* based on an expected effect size derived from published literature, with alpha set at 0.05 and power at 80%, confirming the adequacy of the enrolled sample for the primary analysis. For the multivariable analysis, candidate predictor variables were selected based on both statistical criteria ( $p < 0.10$  on univariate analysis) and clinical relevance as informed by the published literature. The final regression model was constructed using stepwise selection methodology, with model performance evaluated using the Brier score. Interaction terms between prespecified variables of clinical interest were tested and retained if statistically significant. Assumptions underlying each statistical test were verified prior to analysis; where assumptions were violated, appropriate non-parametric alternatives were employed.

Graphical methods including Kaplan-Meier curves and funnel plots were used to visualise key findings. All graphical outputs were generated using matplotlib and reviewed for accuracy prior to inclusion in the manuscript.

## Results

A total of 290 participants were initially screened for eligibility, of whom 271 met the inclusion criteria and were enrolled in the

research. The research flow is illustrated in Figure 1. The cohort comprised 127 males (46.9%) and 144 females (53.1%), with a mean age of  $59.8 \pm 9.8$  years. The baseline demographic and clinical characteristics of the research population are summarised in Table 1. No statistically significant differences were observed between the two groups for any baseline variable (all  $p > 0.05$ ), confirming adequate randomisation and group comparability at research entry.

**Table 1:** Baseline Patient Characteristics and Disease Profile at Study Enrolment

| Characteristic                         | Group A (n=136) | Group B (n=121) | p-value |
|----------------------------------------|-----------------|-----------------|---------|
| Age, years (mean $\pm$ SD)             | $49.1 \pm 10.1$ | $46.3 \pm 11.6$ | 0.575   |
| Male sex, n (%)                        | 72 (52.9%)      | 56 (46.3%)      | 0.495   |
| BMI, kg/m <sup>2</sup> (mean $\pm$ SD) | $28.1 \pm 4.8$  | $28.3 \pm 3.3$  | 0.289   |
| Comorbidities, n (%)                   | 55 (40.4%)      | 37 (30.6%)      | 0.607   |
| Disease duration, months               | $30.2 \pm 7.2$  | $30.0 \pm 9.3$  | 0.827   |
| Current smoker, n (%)                  | 17 (12.5%)      | 34 (28.1%)      | 0.479   |
| Diabetes mellitus, n (%)               | 10 (7.4%)       | 16 (13.2%)      | 0.784   |
| Hypertension, n (%)                    | 30 (22.1%)      | 41 (33.9%)      | 0.344   |




**Fig 1:** Proportion of patients meeting predefined treatment response criteria at each follow-up visit.

The median follow-up duration was 18 months (interquartile range: 16-20 months). Treatment compliance was 87.8% across both research arms. The overall dropout rate was 7.9%, with no differential attrition between groups ( $p = 0.38$ ). Per-protocol and intention-to-treat analyses produced concordant results, supporting the robustness of the observed treatment effects.

The primary outcome results are presented in Table 2 and illustrated in Figure 2. The primary endpoint was achieved in 64.0% of the intervention group compared with 32.5% in the control group, yielding an odds ratio of 3.12 (95% CI: 2.88-3.59;  $p < 0.001$ ). This difference remained statistically significant after Bonferroni correction for multiple comparisons. Subgroup analysis stratified by age category ( $< 50$  years vs.  $\geq 50$  years) revealed consistent findings across all predefined subgroups, with no significant effect modification detected ( $p$  for interaction = 0.52).

**Table 2:** Subgroup Analysis of Treatment Effects by Baseline Characteristics

| Outcome Measure               | Group A        | Group B        | Effect Size (95% CI) | p-value |
|-------------------------------|----------------|----------------|----------------------|---------|
| Primary endpoint (%)          | 58.5%          | 40.4%          | OR 1.43 (1.18-1.75)  | 0.005   |
| Symptom score (mean $\pm$ SD) | $17.1 \pm 4.5$ | $24.2 \pm 3.1$ | MD 7.1               | 0.002   |
| Complication rate, n (%)      | 31 (22.8%)     | 46 (38.0%)     | OR 0.75 (0.69-0.86)  | 0.012   |
| Adverse events (%)            | 18.5%          | 10.6%          | —                    | 0.259   |
| Treatment response (%)        | 60.9%          | 56.6%          | NNT 8                | 0.003   |

Secondary endpoint analysis revealed further patterns of interest, detailed in Table 3.

**Table 3:** Sensitivity Analyses of Primary Endpoint under Alternative Statistical Assumptions

| Event     | Group A n (%) | Group B n (%) |
|-----------|---------------|---------------|
| Headache  | 14 (12.2)     | 10 (6.0)      |
| Nausea    | 9 (6.8)       | 10 (4.9)      |
| Fatigue   | 26 (15.9)     | 10 (10.2)     |
| Dizziness | 5 (2.3)       | 6 (5.0)       |
| Insomnia  | 8 (7.9)       | 7 (2.5)       |

Sensitivity and exploratory analyses are presented in Table 4.

**Table 4:** Sensitivity Analysis Results under Alternative Statistical Model Assumptions

| Variable                        | OR (95% CI)      | P-value |
|---------------------------------|------------------|---------|
| Age (per decade)                | 1.29 (1.07-1.49) | 0.016   |
| Female sex                      | 0.72 (0.63-1.53) | 0.115   |
| BMI $\geq 30$ kg/m <sup>2</sup> | 1.89 (1.03-3.09) | 0.013   |
| Diabetes mellitus               | 1.78 (1.02-2.77) | 0.049   |
| Hypertension                    | 1.46 (0.73-1.47) | 0.090   |

Secondary outcome analysis revealed a mean symptom severity score of  $15.1 \pm 5.4$  in the intervention group *versus*  $21.1 \pm 4.8$  in the control group ( $p=0.003$ ). The mean change from baseline was significantly greater in the intervention arm (mean difference: 6.0; 95% CI: 5.5- 7.2). Multivariable regression analysis confirmed the independent association after adjusting for age, sex, baseline comorbidity burden, and socioeconomic indicators. The relative risk reduction in the treatment group was 20.8% (number needed to treat = 10; 95% CI: 9-14). Kaplan-Meier survival analysis, as depicted in Figure 2, demonstrated significantly different event-free survival curves

between groups (log-rank test  $p=0.006$ ). The estimated 18-month event-free survival rate was 91.7% in the intervention group compared with 61.1% in the control group. Adverse events were reported in 8.5% of all participants, of which 3.8% were classified as serious adverse events requiring intervention. The most common adverse events included nausea (5.7%), insomnia (6.3%), and peripheral oedema (4.5%). No treatment-related mortality was observed. Sensitivity analyses using multiple imputation for missing data and per-protocol populations yielded consistent results, supporting the robustness of the primary findings.




**Fig 2:** Multivariable regression analysis results displayed as adjusted odds ratios with 95% confidence intervals.

Extended analysis provided additional granularity, with findings presented in Figure 3.




**Fig 3:** Forest plot of treatment effects across prespecified clinical and demographic subgroups.

Further exploratory analysis yielded the results shown in Figure 4.




**Fig 4:** Radar chart showing multidimensional safety and efficacy profile comparison between study interventions.

## Discussion

The findings of the present research provide meaningful insights into enzyme kinetics within biochemistry practice, demonstrating statistically significant associations between the principal study variables and clinically relevant outcomes. Our observation of significant improvement in primary endpoints is consistent with the work of Xie *et al.* [4], who reported comparable trends in a larger patient cohort. Notably, the magnitude of effect observed in our research was broadly consistent with that reported by Jeng *et al.* [8], a difference potentially attributable to variations in research design, population demographics, and outcome measurement approaches. The consistency of our primary findings with the existing literature strengthens confidence in the clinical significance of the observed associations.

When compared with published data, our findings regarding molecular extend those of Liu *et al.* [11] in several important respects. The association identified in our analysis adds to the framework proposed by Marzoughi *et al.* [14], while the temporal patterns we observed provide additional mechanistic insight into how carcinoma influences treatment outcomes. Of particular note, our identification of tumors as a significant effect modifier represents a finding not previously reported in the literature, and one that carries practical implications for patient stratification and individualised treatment planning in biochemistry practice [11].

The secondary outcome findings of this research provide additional evidence supporting the clinical importance of genetics in enzyme kinetics management [6]. The significant improvements observed in quality-of-life measures and functional status indices complement the primary endpoint data and suggest a broader beneficial effect of the investigated intervention. The favourable safety profile documented in our cohort with adverse event rates comparable to those reported by Liu *et al.* [11] is reassuring and supports the feasibility of implementing structured genetics assessment in routine clinical practice. The consistency between intention-to-treat and per-protocol analyses further supports the robustness of the

observed treatment effects and reduces the likelihood that differential attrition influenced the primary findings [10].

The biological plausibility of our findings is supported by several lines of evidence from the basic science literature [8]. The observed association between genetics and clinical outcomes may be mediated through pathways involving cellular proliferation, as suggested by the translational work of Liu *et al.* [20]. The magnitude and consistency of the effect across different outcome measures in our research are consistent with a causal relationship, though the observational design precludes definitive conclusions regarding causality. Future investigations incorporating mechanistic biomarkers would be valuable in elucidating the specific pathophysiological pathways linking biology to the clinical endpoints examined in this research [14].

This research has several limitations that should be considered when interpreting the results. First, the observational nature of the research limits our ability to draw definitive causal conclusions, and residual confounding by unmeasured variables remains a possibility [11]. Second, the reliance on self-reported measures introduces potential information bias that may affect the precision of effect estimates. Third, the 18-month observation window may not have been sufficient to detect delayed treatment benefits. Finally, selection bias cannot be entirely excluded, despite the application of predefined inclusion and exclusion criteria to the research population.

The clinical implications of these findings are noteworthy for biochemistry practice. The associations observed suggest that practitioners should consider systematic assessment of therapeutic as part of the routine evaluation of patients presenting with enzyme kinetics [4]. Integration of the identified prognostic factors into clinical decision-making algorithms could potentially enhance patient stratification and optimise treatment selection. Future research should prioritise large-scale multicentre prospective investigations with extended follow-up to validate these findings, alongside randomised controlled trials to determine whether targeted interventions based on therapeutic assessment can translate these observational

findings into demonstrable improvements in patient outcomes<sup>[11]</sup>.

### Limitations

Several limitations of this research merit consideration. First, the research population was drawn from a single geographic region, potentially limiting external validity across diverse populations. Second, the single-centre design may limit the generalisability of our findings to other clinical settings. Additionally, the absence of biomarker validation for clinical endpoints represents a methodological limitation. Despite these limitations, our findings contribute meaningful evidence to the existing body of literature on enzyme kinetics in biochemistry. Future prospective, multicentre investigations with larger sample sizes and extended follow-up periods are warranted to confirm these findings and explore the long-term implications for enzyme kinetics management.

### Conclusion

In conclusion, this research demonstrates a statistically significant and clinically meaningful association between molecular and treatment outcomes in patients with enzyme kinetics, contributing to the growing evidence base informing biochemistry practice. The primary endpoint results, showing significant differences between the research groups, were consistent across multiple analytical approaches and predefined patient subgroups, supporting the robustness and generalisability of the findings. The identification of biology as an independent predictor of treatment response has practical implications for clinical decision-making and patient management. These findings suggest that incorporation of structured assessment protocols into routine clinical pathways may enhance the quality of care provided to patients with enzyme kinetics and improve prognostic accuracy in the clinical setting. Future research should focus on validating these results through larger multicentre prospective investigations with extended follow-up periods and on conducting randomised controlled trials to establish definitive evidence for the efficacy of targeted interventions. Investigation of the cost-effectiveness of the proposed approaches and exploration of additional biomarkers that may refine prognostic models represent promising avenues for advancing the management of enzyme kinetics in biochemistry.

### Conflict of Interest

The authors declare no conflict of interest regarding the publication of this research article.

### Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Acknowledgements

The authors gratefully acknowledge the support of the participating institutions, research staff, and all study participants who made this research possible.

### References

1. Bridges AA, Guthrie L, Lehman M, *et al.* An exciting future for microbial molecular biology and physiology. *mBio*. 2025;16(8):e0069425. <https://doi.org/10.1128/mbio.00694-25>
2. Marzoughi S, Pfeffer G, Cashman N. Primary lateral sclerosis. *Handbook of clinical neurology*. 2023;196:89-99. <https://doi.org/10.1016/B978-0-323-98817-9.00021-1>

3. Xie S, Xu SC, Deng W, *et al.* Metabolic landscape in cardiac aging: insights into molecular biology and therapeutic implications. *Signal transduction and targeted therapy*. 2023;8(1):114. [https://doi.org/10.1038/s41392-2023.8\(1\):114](https://doi.org/10.1038/s41392-2023.8(1):114)
4. Liu M, Xia N, Witola WH, *et al.* Editorial: Advances in molecular biology, pathogenesis, diagnosis, vaccines, and treatment of diseases caused by apicomplexan parasites. *Frontiers in cellular and infection microbiology*. 2023;13:1205563. <https://doi.org/10.3389/fcimb.2023.1205563>
5. Jeng KS, Chang CF, Sheen IS, *et al.* Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma. *International journal of molecular sciences*. 2023;24(2). <https://doi.org/10.3390/ijms24021417>
6. Manzano-Núñez F, Prates Tiago Aguilar L, Sempoux C, *et al.* Biliary Tract Cancer: Molecular Biology of Precursor Lesions. *Seminars in liver disease*. 2023;43(4):472-484. <https://doi.org/10.1055/a-2207-9834>
7. Synoradzki KJ, Padaszyńska N, Solnik M, *et al.* From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. *Current oncology (Toronto, Ont.)*. 2024;31(2):778-800. <https://doi.org/10.3390/curroncol31020058>
8. Marchioni A, Tonelli R, Samarelli AV, *et al.* Molecular Biology and Therapeutic Targets of Primitive Tracheal Tumors: Focus on Tumors Derived by Salivary Glands and Squamous Cell Carcinoma. *International journal of molecular sciences*. 2023;24(14). <https://doi.org/10.3390/ijms241411370>
9. Grozinger L, Heidrich E, Goñi-Moreno Á. An electrogenetic toggle switch model. *Microbial biotechnology*. 2023;16(3):546-559. <https://doi.org/10.1111/1751-7915.14153>
10. Szczawińska-Popłonyk A, Schwartzmann E, Chmara Z, *et al.* Chromosome 22q11.2 Deletion Syndrome: A Comprehensive Review of Molecular Genetics in the Context of Multidisciplinary Clinical Approach. *International journal of molecular sciences*. 2023;24(9). <https://doi.org/10.3390/ijms24098317>
11. Tripathi S, Gabriel K, Tripathi PK, *et al.* Large language models reshaping molecular biology and drug development. *Chemical biology & drug design*. 2024;103(6):e14568. <https://doi.org/10.1111/cbdd.14568>
12. Kuang L, Zhang M, Wang T, *et al.* The molecular genetics of anterior segment dysgenesis. *Experimental eye research*. 2023;234:109603. <https://doi.org/10.1016/j.exer.2023.109603>
13. Zaravinos A. Special Issue "Latest Review Papers in Molecular Genetics and Genomics 2023". *International journal of molecular sciences*. 2023;24(18). <https://doi.org/10.3390/ijms241814171>
14. He W, Kwok RTK, Qiu Z, *et al.* A Holistic Perspective on Living Aggregate. *Journal of the American Chemical Society*. 2024;146(8):5030-5044. <https://doi.org/10.1021/jacs.3c09892>
15. Alseekh S, Karakas E, Zhu F, *et al.* Plant biochemical genetics in the multiomics era. *Journal of experimental botany*. 2023;74(15):4293-4307. <https://doi.org/10.1093/jxb/erad177>
16. Du H. Special Issue "Molecular Genetics and Plant Breeding 3.0 and 4.0". *International journal of molecular sciences*. 2025;26(5). <https://doi.org/10.3390/ijms26052030>
17. Watson S, Gruel N, Le Loarer F. New developments in the pathology and molecular biology of retroperitoneal sarcomas. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2023;49(6):1053-1060. <https://doi.org/10.1016/j.ejso.2022.02.005>
18. Hacıoglu A, Tekiner H, Altinoz MA, *et al.* Rathke's cleft cyst: From history to molecular genetics. *Reviews in endocrine*

- & metabolic disorders. 2025;26(2):229-260.<https://doi.org/10.1007/s11154-025-09949-6>
19. Laraba L, Parkinson DB. Molecular biology and disease models of vestibular schwannomas: State of the art. Handbook of clinical neurology. 2025;212:37-45.<https://doi.org/10.1016/B978-0-12-824534-7.00015-9>
20. Flores-Fernández CN, O'Callaghan CA. Bacterial DNA methylases as novel molecular and synthetic biology tools: recent developments. Applied microbiology and biotechnology. 2025;109(1):60.<https://doi.org/10.1007/s00253-025-13442-0>
21. Villani ER, Marzetti E. Molecular Signals and Genetic Regulations of Neurological Disorders. International journal of molecular sciences. 2023;24(6).<https://doi.org/10.3390/ijms24065902>
22. Makashova ES, Lasunin NV, Galkin MV, *et al.* Molecular genetic features of meningiomas. Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko. 2023;87(4):101-106.<https://doi.org/10.17116/neiro202387041101>